Proton pump inhibitors (PPIs) are widely used to treat disorders characterized by excessive gastric acid production [1] and have been sold over-the-counter for more than one decade. Alongside, PPIs are used for gastroprotection in patients on dual antiplatelet therapy consisting of asprin in combination with a P2Y12 inhibitor such as clopidogrel, prasugrel or ticagrelor to prevent secondary myocardial infarctions and ischaemic strokes. Two different questions, therefore, arise regarding a potentially increased cardiovascular risk associated with PPI intake.
